AbbVie Slips Post-Q2 as Street Upgrades Collide With a Softer Stock
ABBV has pulled back 3.2% this week to $250.94 — its first meaningful retreat since the mid-June trough — arriving just days after Q2 results that the analyst community greeted with fresh target raises but the market…